Six Pharma CEOs To Testify In House as Democrats, Trump Compete For Attention On Drug Pricing
Executive Summary
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.
You may also be interested in...
Revlimid And Copaxone Pricing: Five Not-So-Revealing Revelations From The House Reports
Investigative reports from the House Oversight and Reform Committee recount well-known records of significant price increases for the drugs, the lack of pricing restraints in the US relative to markets abroad, tactics used to protect the drugs from generic competition and the 'return on investment' from manufacturer assistance programs.
US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches
Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.
US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches
Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: